GNOM vs. CNCR

Last updated Jun 5, 2026

GNOM (Global X Genomics & Biotechnology ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - GNOM tracks the Solactive Genomics Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. GNOM charges 0.50%/yr vs 0.79%/yr for CNCR.

Performance

GNOM vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

GNOM

• 1D: 3.47%
• 1M: 11.33%
• YTD: 11.56%
• 6M: 9.34%
• 1Y: 57.90%
• 3Y*: 0.45%
• 5Y*: -9.59%
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
GNOM Global X Genomics & Biotechnology ETF	9.93%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

GNOM vs. CNCR - Sectors Allocation Comparison

Sectors	GNOM	CNCR
Healthcare	99.6%	96.6%
Technology	0.4%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

GNOM vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM

GNOM Risk / Return Rank: 62
GNOM Sharpe Ratio Rank: 67
GNOM Sortino Ratio Rank: 68
GNOM Omega Ratio Rank: 58
GNOM Calmar Ratio Rank: 66
GNOM Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNOM	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	2.18	—	—
Sortino ratio: Return per unit of downside risk	3.06	—	—
Omega ratio: Gain probability vs. loss probability	1.35	—	—
Calmar ratio: Return relative to maximum drawdown	3.20	—	—
Martin ratio: Return relative to average drawdown	9.21	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	GNOM	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.18	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	—	—

Drawdowns

GNOM vs. CNCR - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for GNOM and CNCR.

Drawdown Indicators

	GNOM	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-75.00%	0.00%	-75.00%
Max Drawdown (1Y) Largest decline over 1 year	-18.17%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-46.47%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-72.29%	—	—
Current Drawdown Current decline from peak	-53.90%	0.00%	-53.90%
Average Drawdown Average peak-to-trough decline	-40.56%	0.00%	-40.56%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.30%	—	—

Volatility

Volatility by Period

	GNOM	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.77%	—	—
Volatility (6M) Calculated over the trailing 6-month period	19.72%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	26.66%	0.00%	+26.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.61%	0.00%	+33.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.19%	0.00%	+34.19%

GNOM vs. CNCR - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

GNOM vs. CNCR - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.23%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GNOM Global X Genomics & Biotechnology ETF	1.23%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%

Frequently Asked Questions

Which ETF is better, GNOM or CNCR?

On fees, GNOM is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, GNOM or CNCR?

GNOM is cheaper with a 0.50% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, GNOM or CNCR?

GNOM has the higher dividend yield at 1.23%, compared with 0.00% for CNCR.

What is the main difference between GNOM and CNCR?

GNOM tracks Solactive Genomics Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Global X and Exchange Traded Concepts. Their fees differ too: 0.50% for GNOM and 0.79% for CNCR.